Human Respiratory Syncytial Virus (RSV) is a leading cause of respiratory diseases, it often spreads from respiratory secretions through close contact with an infected person. The virus causes infections at all ages, but young infants of 1–3 months of age have highest incidence rate. In severe cases RSV can lead to bronchiolitis and pneumonia in babies. According to WHO, RSV has been estimated to cause 34 million acute lower respiratory tract infections (LRTI) in young children annually. RSV is a high-priority target for vaccine development because there are no approved products to protect against the respiratory virus. Moreover, it has also estimated that in United States, by the age of two, nearly all children are likely to be infected with RSV.

Increasing incidences of respiratory infection, rising neonatal population, development of drugs & vaccines with better effectiveness and limited drug toxicity can be attributed to the growing demand for global respiratory syncytial virus vaccines market in the coming years. For instance, NOVAVAX, Inc. is projected to launch the RSV F vaccine to prevent RSV infection by 2020.

Key companies are accelerating robust product development pipeline. GlaxoSmithKline, Novavax, Johnson & Johnson's Janssen, AstraZeneca's MedImmune and Bavarian Nordic are some companies working on RSV immunizations. GSK and MedImmune are in phase 2, while Janssen, Vaxart and others are in phase 1, according to a vaccine industry report from PhRMA.

To gather deep-rooted insights with respect to market dynamics, competitive landscape and to unlock the market potential of Respiratory Syncytial Virus (RSV) Vaccines manufacturing, subscribe to the report by clicking and filling up the ‘Pre-book’ section.